ArticleNature materials2026
In situ-generated vaccine-like pyroptosome for personalized cancer immunotherapy.
Article in Nature materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- The paradoxes of interfacial electrolyte structures.Nature materials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
The efficacy of in situ cancer vaccination has been hampered by a poor spatiotemporal orchestration of multiple key steps of the cancer-immunity cycle in most tumours and systemic toxicity related to therapeutic strategies. Here we report a systemic injectable and pyroptosis-enabled nanoadjuvant that evokes the secretion of a vaccine-like pyroptosome in the tumour area for robust antitumour immunity. This systemic injectable and pyroptosis-enabled nanoadjuvant induces vigorous immunogenic pyroptosis, triggering the efficient release of tumour antigen-rich pyroptosomes, damage-associated molecular patterns and proinflammatory cytokines. Photoactivatable release of a TLR7/8 agonist into the pyroptosome generates an in situ cancer vaccine platform that cooperatively activates the cancer-immunity cycle and avoids systemic toxicity. The vaccine boosts both innate and adaptive immune responses, facilitating the eradication of primary tumours and metastatic nodules, thereby providing long-lasting cancer prevention. Overall, the rational design of pyroptosis-inducing nanomedicines for boosting the cancer-immunity cycle reported here might aid in the development of more efficient personalized cancer immunotherapy approaches.
Indexed as
Identifiers
41775900What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.